BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/17/2016 12:43:00 PM | Browse: 1228 | Download: 2276
Publication Name World Journal of Gastrointestinal Surgery
Manuscript ID 22875
Country India
ISSN 1948-9366 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Therapeutics Advances
Article Title Targeted therapy of gastrointestinal stromal tumours
Manuscript Source Invited Manuscript
All Author List Ashish Jakhetiya, Pankaj Kumar Garg, Gaurav Prakash, Jyoti Sharma, Rambha Pandey and Durgatosh Pandey
Funding Agency and Grant Number
Corresponding Author Dr. Pankaj Kumar Garg, Associate Professor, Department of Surgery, University College of Medi­cal Sciences and Guru Teg Bahadur Hospital, University of Delhi, Dilshad Garden, Delhi 110095, India. dr.pankajgarg@gmail.com
Key Words Gastrointestinal tumors; Molecular targeted therapy; Protein kinase inhibitors; Imatinib; Survival
Core Tip Gastrointestinal stromal tumors (GISTs) are common mesenchymal tumours of the gastrointestinal tract. They are characterized by the presence of a driver kinase-activating mutation in either CD-117 or platelet-derived growth factor receptor α. Development of tyrosine kinase inhibitors has led to a paradigm shift in the management of GISTs. Surgery is the primary modality of treatment in localized non-metastatic GISTs. Adjuvant Imatinib for three years is a preferred option for high-risk patients to lessen disease recurrence. The role of neoadjuvant Imatinib is evolving. Imatinib, Sunitinib, and Regorafinib are recommended as first, second and third-line targeted therapies, respectively, for the management of metastatic GISTs.
Publish Date 2016-05-17 12:43
Citation Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D. Targeted therapy of gastrointestinal stromal tumours. World J Gastrointest Surg 2016; 8(5): 345-352
URL http://www.wjgnet.com/1948-9366/full/v8/i5/345.htm
DOI http://dx.doi.org/10.4240/wjgs.v8.i5.345
Full Article (PDF) WJGS-8-345.pdf
Full Article (Word) WJGS-8-345.doc